

AADAC Antibody (monoclonal) (M01)

Mouse monoclonal antibody raised against a partial recombinant AADAC.

Catalog # AT1002a

Specification

AADAC Antibody (monoclonal) (M01) - Product Information

Application	WB, E
Primary Accession	P22760
Other Accession	NM_001086
Reactivity	Human
Host	mouse
Clonality	Monoclonal
Isotype	IgG2b Kappa
Calculated MW	45734

AADAC Antibody (monoclonal) (M01) - Additional Information**Gene ID** 13**Other Names**

Arylacetamide deacetylase, AADAC, DAC

Target/Specificity

AADAC (NP_001077, 201 a.a. ~ 300 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Dilution

WB ~ ~ 1:500 ~ 1000

Format

Clear, colorless solution in phosphate buffered saline, pH 7.2 .

Storage

Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

Precautions

AADAC Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.


AADAC Antibody (monoclonal) (M01) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)

- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

AADAC Antibody (monoclonal) (M01) - Images



Antibody Reactive Against Recombinant Protein. Western Blot detection against Immunogen (36.74 kDa) .



Detection limit for recombinant GST tagged AADAC is approximately 3ng/ml as a capture antibody.

AADAC Antibody (monoclonal) (M01) - Background

Microsomal arylacetamide deacetylase competes against the activity of cytosolic arylamine N-acetyltransferase, which catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine carcinogens

AADAC Antibody (monoclonal) (M01) - References

1. N-Glycosylation during translation is essential for human arylacetamide deacetylase enzyme activity. Muta K, Fukami T, Nakajima M, Yokoi T. *Biochem Pharmacol.* 2013 Oct 11. pii: S0006-2952(13)00651-5. doi: 10.1016/j.bcp.2013.10.001.
2. Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. Kobayashi Y, Fukami T, Higuchi R, Nakajima M, Yokoi T. *Biochem Pharmacol.* 2012 Aug 23. 3. A Novel Polymorphic Allele of Human Arylacetamide Deacetylase Leads to Diminished Enzyme Activity. Shimizu M, Fukami T, Kobayashi Y, Takamiya M, Aoki Y, Nakajima M, Yokoi T. *Drug Metab Dispos.* 2012 Mar 13. [Epub ahead of print]
4. Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. Kobayashi Y, Fukami T, Nakajima A, Watanabe A, Nakajima M, Yokoi T. *Drug Metab Dispos.* 2012 Apr;40(4):671-9. Epub 2011 Dec 29.
5. Human Arylacetamide Deacetylase Is A Principal

Enzyme in Flutamide Hydrolysis. Watanabe A, Fukami T, Nakajima M, Takamiya M, Aoki Y, Yokoi T. *Drug Metab Dispos.* 2009 Jul;37(7):1513-20. Epub 2009 Apr 1.